You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Optimization of a computationally designed antiviral for influenza

    SBC: Virvio Inc            Topic: NIAID

    DESCRIPTION provided by applicant Influenza is a leading cause of death and morbidity in the US resulting in up to deaths hospitalizations and andgt $ billion in expenses per year Current antivirals incur high resistance rates and have low efficacy so there is a crucial need to develop better approaches to protect from seasonal influenza and future pandemics We aim to ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists

    SBC: Bohemica Pharmaceuticals, LLC            Topic: 100

    DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Microfluidic Platform for Stem Cell Applications

    SBC: Nortis, Inc.            Topic: NCATS

    DESCRIPTION provided by applicant The emerging field of stem cell therapy has the potential to transform medicine forever However a major bottleneck for bringing stem cell therapies to the patient is the lack of adequate in vitro assays for the study of stem cell quality Critical test criteria are efficacy pluripotency prior to the differentiation process and safety lack of tumorigenicity ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Clonotyping Technology for Prediction of Antibiotic Resistance

    SBC: ID Genomics SPC            Topic: NIAID

    DESCRIPTIONprovided by applicantThe primary goal of this proposal is to develop and finalize configuration of a rapid molecular diagnostics test to predict antibiotic resistance of th major human uropathogensEscherichia coliKlebsiella pneumoniaeEnterobacter spp and Pmirabilisby determining the sub species clonal identityclonotypeof the infecting bacteria directly from urine samplesCurrentlythe emp ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Aerosol Sampling and Microfluidic Analysis of Reactive Oxygen Species

    SBC: ILLIONIX, LLC            Topic: 113

    DESCRIPTION provided by applicant Cardiovascular diseases and Asthma affects between and million people in the United States including million children during the past years its incidence worldwide has doubled Asthma is responsible for million person days of restricted activity and deaths per year amounting to $ billion in direct heath related costs there is uncertainty about the specific factors ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Optimization of a novel cancer immunotherapeutic antibody for human use

    SBC: CANCURE LLC            Topic: 102

    ABSTRACT The goal of this application is to evaluate the cancer therapeutic feasibility of CanCureandapos s humanized first in class immunostimulatory monoclonal antibody mAb huB G the Product also names CuraB During cancer development in response to oncogenic insult or stress almost ALL human cancer cells are induced to express a SURFACE molecule MIC MHC I chain related Molecule wh ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Therapeutic Potential of the Potassium Channel Inhibitor SHK-186 for Pediatric Lupus

    SBC: KINETA, INC.            Topic: R

    DESCRIPTION provided by applicant Systemic lupus erythematosus SLE is a chronic multisystem autoimmune disease with poorly understood etiology and pathogenesis and for which adequate treatment options are limited Although dysregulated production of autoantibodies and immune complex deposition are considered hallmarks of SLE considerable evidence supports the hypothesis that auto reactive ly ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. A Sparse-readout Quantitative PET scanner for breast cancer therapy optimization

    SBC: PET/X LLC            Topic: 102

    The goal of this project is to develop a quantitative molecular breast imaging PET QMBI PET scanner to improve the way in which breast cancer therapies are matched to individual patients by providing evaluation of therapy efficacy during the window of opportunity between diagnosis and surgical resection More than women in the US with invasive disease start therapy for breast cancer each ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Ultrasensitive SERS Nano-Sensors for Pancreatic Cancer Diagnosis and Prognosis

    SBC: Sanguine Diagnostics And Therapeutics, Inc.            Topic: 103

    ABSTRACT Pancreatic cancer PC is an extremely aggressive malignancy with one of the worst prognoses of all cancers with a median survival of less than one year and an overall year survival of andlt With marked resistance to chemo and radiotherapies surgery is the only curative option In patients with localized disease and no lymph node or extra pancreatic metastases complete surgical ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government